Because Spravato comes with the potential for misuse, it's only available through a restricted distribution system under a Risk Evaluation and Mitigation Strategy (REMS). Meaning, you have to go ...

REMICADE and SIMPONI worldwide sales were positively impacted by return of distribution rights in Europe. In Neuroscience, SPRAVATO growth of 45.3% continues to be driven by increased physician ...

SPRAVATO ® (esketamine ... PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds ...

Morningstar brands and products Company Portfolio ...

EGRIFTA SV® is distributed in the United States only.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.